share_log

JP Morgan Downgrades Agios Pharmaceuticals to Neutral, Announces $54 Price Target

Benzinga Real-time News ·  Mar 1, 2021 18:56

JP Morgan analyst Anupam Rama downgrades Agios Pharmaceuticals (NASDAQ:AGIO) from Overweight to Neutral and announces $54 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment